- Home
- AIRS vs INBX Comparison
AIRS vs INBX Comparison
Compare AIRS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- INBX
- Stock Information
- Founded
- AIRS 2012
- INBX 2010
- Country
- AIRS United States
- INBX United States
- Employees
- AIRS N/A
- INBX N/A
- Industry
- AIRS Medical/Nursing Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- INBX Health Care
- Exchange
- AIRS Nasdaq
- INBX Nasdaq
- Market Cap
- AIRS 249.9M
- INBX 237.5M
- IPO Year
- AIRS 2021
- INBX 2020
- Fundamental
- Price
- AIRS $4.95
- INBX $14.76
- Analyst Decision
- AIRS Hold
- INBX Hold
- Analyst Count
- AIRS 2
- INBX 1
- Target Price
- AIRS $5.50
- INBX N/A
- AVG Volume (30 Days)
- AIRS 111.4K
- INBX 118.3K
- Earning Date
- AIRS 11-07-2024
- INBX 08-13-2024
- Dividend Yield
- AIRS N/A
- INBX N/A
- EPS Growth
- AIRS N/A
- INBX N/A
- EPS
- AIRS N/A
- INBX 118.83
- Revenue
- AIRS $193,025,000.00
- INBX $1,687,000.00
- Revenue This Year
- AIRS N/A
- INBX N/A
- Revenue Next Year
- AIRS $11.85
- INBX N/A
- P/E Ratio
- AIRS N/A
- INBX $0.12
- Revenue Growth
- AIRS 6.58
- INBX 24.26
- 52 Week Low
- AIRS $2.92
- INBX $10.80
- 52 Week High
- AIRS $8.30
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- AIRS 54.52
- INBX 44.24
- Support Level
- AIRS $4.36
- INBX $15.11
- Resistance Level
- AIRS $5.95
- INBX $15.91
- Average True Range (ATR)
- AIRS 0.52
- INBX 0.64
- MACD
- AIRS -0.02
- INBX -0.24
- Stochastic Oscillator
- AIRS 45.57
- INBX 1.62
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.